BLU 945
Alternative Names: BLU-945; ZL-2313Latest Information Update: 07 Jun 2024
At a glance
- Originator Blueprint Medicines
- Developer Blueprint Medicines; ZAI Lab
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer
Most Recent Events
- 07 Jun 2024 Discontinued - Phase-I for Non-small cell lung cancer in China (PO) (Blueprint Medicines Pipeline, June 2024)
- 07 Jun 2024 Discontinued - Phase-I/II for Non-small cell lung cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA, France, Japan, Taiwan, Singapore, Spain, Netherlands, United Kingdom, Germany, South Korea, Canada (PO) (Blueprint Medicines Pipeline, June 2024)
- 07 Jun 2024 Discontinued - Phase-I/II for Non-small cell lung cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in Canada (PO) (Blueprint Medicines Pipeline, June 2024)